🚀 VC round data is live in beta, check it out!
Neurocrine Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Neurocrine Biosciences and similar public comparables like Alteogen, Sino Biopharmaceutical, CSPC Pharma Group, Zhangzhou Pientzehuang and more.
Neurocrine Biosciences Overview
About Neurocrine Biosciences
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Founded
1992
HQ
Employees
2.0K
Website
Financials (LTM)
EV
$12B
Neurocrine Biosciences Financials
Neurocrine Biosciences reported last 12-month revenue of $3B and EBITDA of $734M.
In the same LTM period, Neurocrine Biosciences generated $3B in gross profit, $734M in EBITDA, and $530M in net income.
Revenue (LTM)
Neurocrine Biosciences P&L
In the most recent fiscal year, Neurocrine Biosciences reported revenue of $3B and EBITDA of $667M.
Neurocrine Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | $734M | XXX | $667M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $530M | XXX | $479M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Neurocrine Biosciences Stock Performance
Neurocrine Biosciences has current market cap of $13B, and enterprise value of $12B.
Market Cap Evolution
Neurocrine Biosciences' stock price is $133.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12B | $13B | 3.8% | XXX | XXX | XXX | $4.76 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeurocrine Biosciences Valuation Multiples
Neurocrine Biosciences trades at 4.1x EV/Revenue multiple, and 16.8x EV/EBITDA.
EV / Revenue (LTM)
Neurocrine Biosciences Financial Valuation Multiples
As of April 18, 2026, Neurocrine Biosciences has market cap of $13B and EV of $12B.
Equity research analysts estimate Neurocrine Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neurocrine Biosciences has a P/E ratio of 25.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV (current) | $12B | XXX | $12B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 16.8x | XXX | 18.5x | XXX | XXX | XXX |
| EV/EBIT | 18.5x | XXX | 19.4x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | 4.4x | XXX | XXX | XXX |
| P/E | 25.3x | XXX | 28.0x | XXX | XXX | XXX |
| EV/FCF | 15.8x | XXX | 16.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Neurocrine Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Neurocrine Biosciences Margins & Growth Rates
Neurocrine Biosciences' revenue in the last 12 month grew by 18%.
Neurocrine Biosciences' revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.1M for the same period.
Neurocrine Biosciences' rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neurocrine Biosciences' rule of X is 80% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Neurocrine Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 39% | XXX | 40% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 80% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 35% | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Neurocrine Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Neurocrine Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Alteogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Sino Biopharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| CSPC Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhangzhou Pientzehuang | XXX | XXX | XXX | XXX | XXX | XXX |
| Regencell Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neurocrine Biosciences M&A Activity
Neurocrine Biosciences acquired XXX companies to date.
Last acquisition by Neurocrine Biosciences was on XXXXXXXX, XXXXX. Neurocrine Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Neurocrine Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeurocrine Biosciences Investment Activity
Neurocrine Biosciences invested in XXX companies to date.
Neurocrine Biosciences made its latest investment on XXXXXXXX, XXXXX. Neurocrine Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Neurocrine Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Neurocrine Biosciences
| When was Neurocrine Biosciences founded? | Neurocrine Biosciences was founded in 1992. |
| Where is Neurocrine Biosciences headquartered? | Neurocrine Biosciences is headquartered in United States. |
| How many employees does Neurocrine Biosciences have? | As of today, Neurocrine Biosciences has over 2K employees. |
| Who is the CEO of Neurocrine Biosciences? | Neurocrine Biosciences' CEO is Kyle W. Gano. |
| Is Neurocrine Biosciences publicly listed? | Yes, Neurocrine Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Neurocrine Biosciences? | Neurocrine Biosciences trades under NBIX ticker. |
| When did Neurocrine Biosciences go public? | Neurocrine Biosciences went public in 1996. |
| Who are competitors of Neurocrine Biosciences? | Neurocrine Biosciences main competitors are Alteogen, Sino Biopharmaceutical, CSPC Pharma Group, Zhangzhou Pientzehuang. |
| What is the current market cap of Neurocrine Biosciences? | Neurocrine Biosciences' current market cap is $13B. |
| What is the current revenue of Neurocrine Biosciences? | Neurocrine Biosciences' last 12 months revenue is $3B. |
| What is the current revenue growth of Neurocrine Biosciences? | Neurocrine Biosciences revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Neurocrine Biosciences? | Current revenue multiple of Neurocrine Biosciences is 4.1x. |
| Is Neurocrine Biosciences profitable? | Yes, Neurocrine Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neurocrine Biosciences? | Neurocrine Biosciences' last 12 months EBITDA is $734M. |
| What is Neurocrine Biosciences' EBITDA margin? | Neurocrine Biosciences' last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Neurocrine Biosciences? | Current EBITDA multiple of Neurocrine Biosciences is 16.8x. |
| What is the current FCF of Neurocrine Biosciences? | Neurocrine Biosciences' last 12 months FCF is $780M. |
| What is Neurocrine Biosciences' FCF margin? | Neurocrine Biosciences' last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Neurocrine Biosciences? | Current FCF multiple of Neurocrine Biosciences is 15.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.